RVTYRevvity
Is it growing?
Growth is fading: earnings down −11% year on year and operating margin narrowing (−1.2 points).
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −7% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.
Trailing-twelve-month operating margin, 12.3% now against 13.5% a year earlier.
All from SEC EDGAR, as of Jul 5, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is RVTY growing?
Revvity has grown revenue 0.87% a year over three years and −7.3% a year over five, with earnings per share compounding at −31%.
Revenue growth, 3-year annual rate · Diagnostics & Research median +8.4% · growing slowly · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- −7.3%
Revenue growth, 5-year rate · +0.87% over three · growth has picked up over the last three years
- Earnings per share, 3-year rate
- −31%
Earnings per share, 3-year rate · revenue +0.87% · earnings lagged revenue: the growth is costing something
- Years of annual history on file
- 18
Years of annual history on file · FY2008 to FY2025, as filed
Details›
- Revenue FY2021
- $3.83B
- Revenue FY2022
- $3.31B
- Revenue FY2023
- $2.75B
- Revenue FY2024
- $2.76B
- Revenue FY2025
- $2.86B
Annual income statements as filed with the SEC.
Diagnostics & Research
The closest names by size in the same industry